Utility of a novel estimation method for hemoglobin A1c using glycated albumin in type 2 diabetes mellitus patients with end-stage renal disease

Utility of a novel estimation method for hemoglobin A1c using glycated albumin in type 2 diabetes mellitus patients with end-stage renal disease - Utility of a novel estimation method for hemoglobin A1c using glycated albumin in type 2 diabetes mellitus patients with end-stage renal disease

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036647

Enrollment

100

Registered

2019-05-05

Start date

2017-10-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus patients with end-stage renal disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes patients Over 20 years old,Male and Female written informed consent

Exclusion criteria

Exclusion criteria: Type 1 diabetes patients Patients having severe infections, before and after operation and trauma Pregnancy Patient who are inadequate to enter this study due to the other reasons by physicians judgments

Design outcomes

Primary

Measure	Time frame
Average blood glucose level in Continuous Glucose Monitoring	—

Secondary

Measure	Time frame
HbA1c and GA after CGM	—

Countries

Japan

Contacts

Public ContactYumi Nasu

Osafune Clinic Deputy Nurse Head

osafune-clinic@nifty.com0869-26-8080

Outcome results